bladder cancer

News

FDA rejects ImmunityBio’s bladder cancer drug

Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.

News

FDA approves Adstiladrin as first gene therapy for NMIBC

The US Food and Drug Administration (FDA) has

News

Genentech withdraws US indication of Tecentriq for bladder, ...

Genentech, a

News

NICE reverses stance on Merck's Bavencio for bladder cancer

Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only ca

News

Trial win sets up new use for Astellas, Seagen's Padcev in b...

Astellas and Seagen's Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial.

News

NICE clears NHS use of Roche's Tecentriq in bladder cancer

NICE has recommended routine NHS access to Roche's cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (C

FDA rejects ImmunityBio’s bladder cancer drug

FDA approves Adstiladrin as first gene therapy for NMIBC

Genentech withdraws US indication of Tecentriq for bladder, ...

NICE reverses stance on Merck's Bavencio for bladder cancer

Trial win sets up new use for Astellas, Seagen's Padcev in b...

NICE clears NHS use of Roche's Tecentriq in bladder cancer

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

bladder cancer

Editor's Picks